EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Evolus statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Evolus | Industry median |
|---|---|---|
| Market Cap | $486.13M | $166.30M |
| Enterprise Value | $597.71M | $88.19M |
| PS Ratio | 1.54 | 3.65 |
Enterprise value
| Measure | Evolus | Industry median |
|---|---|---|
| EV / Sales | 1.89 | 2.51 |
Income (trailing twelve months)
| Measure | Evolus | Industry median |
|---|---|---|
| Revenue | $316.49M | $58.34M |
| Gross Profit | $211.21M | $105.94M |
| Operating Income | -$18.67M | -$21.40M |
| Pretax Income | -$33.68M | -$14.34M |
| Net Income | -$34.33M | -$22.46M |
| EBITDA | -$11.40M | -$16.91M |
| EPS (Diluted) | -$0.52 | -$0.83 |
Margins
| Measure | Evolus | Industry median |
|---|---|---|
| Gross Margin | 66.7% | 52.9% |
| Operating Margin | -5.90% | -44.0% |
| Pretax Margin | -10.6% | -13.3% |
| Profit Margin | -10.8% | -40.2% |
| EBITDA Margin | -3.60% | -30.2% |
| FCF Margin | -5.78% | -9.27% |
Returns
| Measure | Evolus | Industry median |
|---|---|---|
| Return on Assets (ROA) | -14.4% | -40.9% |
| Return on Invested Capital (ROIC) | -20.2% | -32.4% |
| Return on Capital Employed (ROCE) | -12.5% | -38.1% |
Growth
| Measure | Evolus | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 13.9% | 5.96% |
| Revenue Growth (3Y CAGR) | 26.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 39.4% | 6.48% |
Balance sheet
| Measure | Evolus | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $45.17M | $61.43M |
| Total Debt | $156.74M | $118.52M |
| Net Cash (Debt) | -$111.57M | $15.35M |
| Net Cash Per Share | -$1.69 | $0.66 |
| Equity (Book Value) | -$30.90M | $49.09M |
| Book Value Per Share | -$0.47 | $1.37 |
| Tangible Book Value | -$97.80M | $23.52M |
| Working Capital | $68.81M | $76.81M |
Financial position
| Measure | Evolus | Industry median |
|---|---|---|
| Current Ratio | 1.70 | 3.34 |
| Quick Ratio | 1.09 | 2.44 |
| Interest Coverage | -1.15 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Evolus | Industry median |
|---|---|---|
| Operating Cash Flow | -$15.38M | -$12.35M |
| Capital Expenditures | -$2.90M | -$1.08M |
| Free Cash Flow | -$18.28M | -$20.22M |
| FCF Per Share | -$0.28 | -$0.42 |
Efficiency
| Measure | Evolus | Industry median |
|---|---|---|
| Asset Turnover | 1.33 | 0.39 |
| Inventory Turnover | 3.13 | 2.70 |
| Revenue Per Employee | $947.57K | $404.87K |
| Profits Per Employee | -$102.79K | -$703.34K |
| Employee Count | 334 | 74 |
Dividends and yields
| Measure | Evolus | Industry median |
|---|---|---|
| Earnings Yield | -7.06% | -23.3% |
| FCF Yield | -3.76% | -8.72% |
Shares
| Measure | Evolus | Industry median |
|---|---|---|
| Shares Outstanding | 66,050,400 | 58,127,000 |
| Shares Change (YoY) | 2.35% | 10.9% |
| Shares Change (QoQ) | 0.26% | 0.54% |
| Float | 63,364,500 | 49,136,700 |
| Shares Held by Insiders | 4.07% | 11.6% |
| Shares Held by Institutions | 84.0% | 59.4% |
Taxes
| Measure | Evolus | Industry median |
|---|---|---|
| Income Tax | $654.00K | $79.87K |
Scores
| Measure | Evolus | Industry median |
|---|---|---|
| Altman Z-Score | -1.43 | -0.22 |
| Piotroski F-Score | 2 | 4 |
| Beneish M-Score | -2.59 | -2.62 |
Calculated by StockData from Evolus's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.